Modified Albumin-Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy.

ABSTRACT: Albumin-bilirubin (ALBI) grade is an objective and reproducible model for evaluating overall survival (OS) in patients with hepatocellular carcinoma (HCC). However, the original ALBI grade was established for patients with Child-Pugh classes A-C. HCC patients with Child-Pugh class C or poor performance status (Barcelona Clinic Liver Cancer (BCLC) stage D) usually receive hospice care. Thus, optimized cutoffs for the ALBI grade for stratifying OS in HCC patients receiving anticancer therapy are pertinent for accurate prognostication. This study retrospectively enrolled 2116 patients with BCLC stages A-C HCC after the exclusion of those ineligible for receiving anticancer therapy. The modified ALBI (mALBI) grades were: an ALBI score ≤-3.02 for mALBI grade 1, an ALBI score >-3.02 to ≤-2.08

SUBMITTER: Hsu WF 

PROVIDER: S-EPMC9600636 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature